Tissue Regeneration Therapeutics (TRT) is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology product TXP-1, by providing licensing opportunities to collaborating partners.

With our partners we create cellular and regenerative strategies that maximize the utility of our platform technology and products - for therapies that address important health care issues of today.

Together, we build very powerful biology.


November 23, 2014 - Tissue Regeneration Therapeutics Inc. (TRT) and Héma-Québec enter a definitive licensing agreement for the first human clinical trial of TXP-1

July 10, 2013 - Tissue Regeneration Therapeutics Inc. (TRT) raises $3.25 Million to accelerate the development of its Mesenchymal Cell therapeutics platform